dergoing bone marrow transplantation and died from fulminant hepatitis, 26 days after the implicated HAV transfusion. Conclusion: The blood donor, a garbage collector, spontaneously returned to the blood bank when developing jaundice. This highlights the importance of donor education to immediately report to blood banks of any signs and symptoms related to infectious disease developed after blood donation. The fact that one immunocompromised patient with HCV infection died from fulminant hepatitis after receiving a HAV-contaminated platelet transfusion underpins the importance of a HAV vaccination program for these group of patients.
Introduction
Hepatitis A virus (HAV) is the most common agent causing acute liver disease, with approximately 1.4 million of new cases occurring every year worldwide [1] . In Brazil, two epidemiological scenarios with low and intermediate HAV endemicity are shown. The anti-HAV IgG seroprevalence varies from 33.7% to 68.8%, for the intermediate and low endemic areas [2] . HAV is a non-enveloped single-stranded RNA picornavirus of the genus Hepatovirus whose most common genotypes found in human infections are the genotypes I and III [1] [2] [3] [4] . Most cases of hepatitis A are self-limited and last 2-3 weeks after onset of symptoms [5] . Hepatitis A carries no risk for development of chronic hepatitis.
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Summary
Background: This paper describes the transmission of hepatitis A virus (HAV) to two blood recipients from a healthy donor that later presented to the blood bank with jaundice. Methods: The RNA of HAV was detected by qualitative nested reverse transcription polymerase chain reaction (nested RT-PCR) and quantified by realtime RT-PCR. HAV RNA samples were genotyped by direct sequencing of PCR products. A sequence from a fragment of 168 bp from the VP1/2A HAV region was used to construct a phylogenetic tree. Case Report: A 31-year-old male donor accepted for donation of a whole blood unit returned to the blood bank with clinical jaundice 20 days after donation. His serological and NAT tests were negative for HBV and HCV. Serological tests for HAV IgM and IgG were negative on donation sample but positive on follow-up sample, confirming donor's HAV acute infection. Both recipients of red blood cells (R1) and platelet concentrate (R2) from the same implicated donation were HAV IgM-negative and IgG-positive. Qualitative PCR was positive on samples from all three individuals and phylogenetic analysis of viruses proved HAV transmission to the two recipients of blood products. HAV viral load on donor follow-up sample and the platelet recipient was 1.3 and 1.5 × 10 3 IU/ml, respectively. The RBC recipient, also infected by HCV, was un-The HAV incubation period usually lasts 2-7 weeks (average 28 days) prior to the onset of signs and symptoms. Viremia and fecal shedding often peak 2 weeks before symptoms appear. Laboratory findings are typical of hepatocellular injury with a marked elevated alanine aminotransferase (ALT) that precedes the elevation of serum bilirubin levels by a few days. When symptoms develop, IgM is frequently detected and confirms cases of hepatitis A [1, 5] .
Usually the main route of transmission is fecal-oral, through contaminated food and water [1, 5] . Because viremia develops before symptoms onset transfusion transmission by whole blood, fresh-frozen plasma, platelet concentrates, and red blood cells (RBCs) has been sporadically described since 1974 [6] [7] [8] [9] . However, in these reports it was difficult to demonstrate direct virological links between blood components and HAV infection.
Using molecular methods, Gowland et al. [10] documented one case of HAV transmission by RBCs to a recipient that was anti-HAV IgG-positive. The recipient did not develop hepatitis A but viremia ensued 2.5 months later along with elevation of IgG titer. Sequencing of HAV RNA from both the donor's and recipient's samples confirmed the transfusion link between individuals.
This article describes two cases of HAV transmission by blood transfusion from one infected donor. The two recipients were anti-HAV IgG-positive; nevertheless, both developed viremia, and one had elevated liver enzymes and symptoms characteristic of HAV infection. Molecular sequencing of the isolated HAV RNA from the three individuals confirmed the transfusion transmissions of HAV.
Material and Methods
Ethics
This investigation was approved by the Ethics Committee of the National Cancer Institute, Rio de Janeiro, Brazil, under the registration number 100/13.
Blood Collection and Manufacturing
The donor's whole blood was collected on CPDA-1 bag. RBCs and plateletrich plasma were obtained after centrifugation of whole blood within 4 h of completion of the phlebotomy. The platelet concentrate was prepared by additional heavy-spin centrifugation, followed by removal of supernatant plasma. The platelet concentrate was stored under continuous agitation at a temperature between 20 and 24 ° C, and the RBCs were stored at a temperature between 4 and 8 ° C. The platelet concentrate was integrated into a pool of platelets that was transfused into a patient (blood recipient R1). The RBC concentrate was filtered and irradiated before transfused into another patient (blood recipient R2). The remaining plasma unit was discarded.
Biochemical Tests
Testing for alanine aminotransferase (ALT) is not mandatory for blood donor screening in Brazil; thus samples from the implicated donor and blood recipients were referred to the clinical laboratory where serum levels of ALT and total bilirubin were measured on a Roche/Hitachi Cobas 501 analyzer (Roche Diagnostics GmbH, Grenzach-Wyhlen, Germany). The values obtained are within the set limits, according to the manufacturer's instructions.
Serological Assays and Nucleic Acid Test (NAT)
The presence of anti-HAV IgM and IgG antibodies was investigated in serum samples using a qualitative microparticle chemiluminescence immunoassay on the Architect system Module i2000 (Abbott, North Chicago, IL, USA). In addition to HAV serological assays, blood donor samples were screened for Trypanosoma cruzi, syphilis, HTLV-1/2, HIV1/2, HCV, and HBV (HBsAg and anti-HBc) by serological assays on the Architect platform and for HIV, HCV, and HBV by NAT performed on minipools of six samples using Cobas TaqScreen MPX test, v2.0 on the Cobas s 201 System (Roche Molecular Diagnostics, Pleasanton, CA, USA). Except for HBV NAT, all assays were mandatory by Brazilian government regulations.
Qualitative Nested RT-PCR
The viral RNA was extracted from 140 μl of serum using the QIAmp Viral RNA Kit (Qiagen, Valencia, CA, USA). Reverse transcription was performed at 55 ° C for 1 h using 10 μl of RNA, RNasin (30 U/μl) (Invitrogen, Carlsbad, CA, USA), random primer (20 pmol/μl) (Invitrogen, Rockville, MD, USA), dNTP (1.25 mmol/l) (Invitrogen, Carlsbad, CA, USA) and Superscript III transcriptase (200 U/μl) (Invitrogen, Carlsbad, CA, USA). The VP1/2A (247 bp) of the HAV genome was amplified using a nested RT-PCR as previously described [11] . The PCR products were loaded onto a 1.5% agarose gel and stained with ethidium bromide. Fragments of the expected size (247 bp) were purified using the QIAquick PCR purification kit (Qiagen) according to the procedure described by the manufacturer.
Real-Time RT-PCR
The HAV RNA was quantified from 5 μl of the cDNA with the TaqMan real-time PCR assay using an Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). To quantify HAV RNA, a recombinant clone of the 5' non-coding region (5' NCR) of the HAV (strain HAF-203) was used as standard curve, and primers specific for the 5' NCR of HAV and one HAV probe labeled with 5-carboxyfluorescein were used as described previously [12] . The detection limit reported for this assay was 14 copies/ml (3.3 IU/ml) [12] . The viral load results were described as IU/ml, after applying a conversion factor of 4.2 [13] .
HAV Sequencing
HAV RNA samples were genotyped by direct sequencing of PCR products by using internal primers and the ABI PRISM Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) in a Gene Amp PCR System 9700 (Applied Biosystems) [14] . The sequence of 168 bp VP1/2A was used to construct a phylogenetic tree [15] . The HAV genotype is determined by the inclusion of previously published HAV sequences of different genotypes, including genotype strain IA-15, IB strains HM-175 (Australia), and HAF-203 (Brazil), strain IIA SLF88 (Sierra Leone) strain IIB CF-53 (France) , and IIIA strain GA76.
Case Report
The implicated donor is a 31-year-old male accepted for donation of a whole blood unit on December 10, 2011. All his serological screening tests were non-reactive as were the HIV, HCV and HBV NAT. 20 days after donation (on December 30, 2011), he returned to the blood bank service with clinical evidence of jaundice. An investigation of possible transmission of a hepatitis virus was initiated and new sample collected. All donor regulatory screening tests, including HCV and HBV NAT testing, were again non-reactive. As part of the protocol for lookback investigation of transfusion transmission of hepatitis, the serum levels of ALT and total bilirubin were evaluated, and both were elevated (ALT = 680 U/ml and total bilirubin = 7.75 mg/dl). Because the donor is a garbage collector a suspicion of HAV infection was raised, and anti-HAV IgM and IgG antibody tests were carried out and both found reactive.
A sample from the donation day was recovered from the serum repository and tested for anti-HAV IgM and IgG antibodies being non-reactive for both tests. These results characterize an anti-HAV antibody seroconversion confirming the diagnosis of HAV acute infection.
The two recipients of blood components from the same implicated donation have been identified. The first blood component recipient (R1) was a 27-year-old man under chemotherapy for acute myeloid leukemia (AML). He received a transfusion of platelets from the implicated donor on December 12, 2011. His liver enzymes and clinical symptoms were monitored during the 49 days since the platelet transfusion and hospital discharge. During this period he did not show elevated levels of liver enzymes or clinical symptoms of hepatitis. He died on July 2012 of causes related to his underlying disease.
The second blood component recipient (R2) was a 39-year-old man diagnosed with myelodysplastic syndrome, undergoing post-bone marrow transplant immunosuppression and being a chronic carrier of HCV. He received transfusion of RBCs on December 14, 2011, and on January 5, 2012 (22 days after transfusion) serum levels of both ALT and total bilirubin were elevated ( fig. 1) . The patient died from fulminant hepatitis on January 9, 2012, 26 days after the RBC transfusion. Of note, on the day of his death the HCV viral load was 2.57 × 10 6 IU/ml, a value almost 19 times greater than the HCV viral load of 1.36 × 10 5 IU/ml measured on August 2011. Serum samples from the two patients collected on January 5, 2012 (R2) and January 8, 2012 (R1) were tested for anti-HAV IgM and IgG (table 1). Sera from both recipients were reactive for anti-HAV IgG but non-reactive for anti-HAV IgM.
These two samples, along with donor's second sample were evaluated by qualitative nested RT-PCR directed to the VP1/2A region (247 bp). All three samples were positive, as shown on figure 2 . Furthermore, quantitative realtime RT-PCR was performed on samples from donor (sample from December 30, 2011) and from platelet recipient with viral load of 1.3 × 10 3 and 1.5 × 10 3 IU/ml, respectively. There was not enough sample volume from R2 patient to perform real-time RT-PCR.
A phylogenetic tree based on 168 nucleotide sequences in the HAV VP1/2A region was constructed ( fig. 3 ). All three viruses sequenced were genotyped as HAV IA. Relatedness between the donor's and recipients' virus sequence was evidenced in this analysis further confirming the HAV transmission by transfusion.
Discussion
We reported two cases of transmission of HAV via blood transfusion with blood products originated from one blood donor. He was asymptomatic and anti-HAV IgM-and IgG-negative at the time of donation, but 20 days later, when he returned to the blood bank, he had jaundice as well as elevated levels of ALT and total bilirubin. Moreover, anti-HAV IgM became positive, and viremia (1.3 × 10 3 IU/ml) could be detected by PCR. It is likely therefore that blood donation took place during the HAV incubation period.
In adults, HAV infection has an average period of 28 days before symptom onset. In general, viremia precedes peak of liver enzymes by 2 weeks and may last for several months after symptoms disappear [17] . The donor case fitted well with this data. The donor is a garbage collector and may have acquired HAV infection through occupational exposure possibly during collection of contaminated water and/or food. Due to the high risk of occupational exposure to HAV infection, health authorities should reevaluate the standards and encourage the practice of vaccination against hepatitis A for this category of workers.
Although viremia was detected in the two blood transfusion recipients, their clinical courses were very distinctive. R1 died 7 months after blood transfusion of causes unrelated to HAV infection but did not show elevated levels of liver enzymes until 49 days after blood transfusion, when he was discharged from the hospital. It is possible that pre-existing IgG were activated by the infection and partially neutralized the virus, which as a consequence, led to a sub-clinical infection. Corroborating this hypothesis are studies with passive immunization with immunoglobulin that can completely suppress or modify the infection in HAV-susceptible persons depending on the concentration of anti-HAV administered [18] . This case is similar to the one described by Gowland et al. [10] and adds platelets concentrate as source of HAV transmission by transfusion.
R2, however, died 26 days after blood transfusion from fulminant hepatitis, and the level of ALT peaked 2 days before death. Importantly, R2 was under immunosuppressive drugs since before the blood transfusion which may have impaired a normal immune response including IgG burst induced by infection. In this scenario, pre-existing anti-HAV IgG may not have been sufficient to completely neutralize the virus. Moreover, R2 had a chronic HCV infection, a condition that when superimposed by HAV infection is associated with a high risk of developing fulminant hepatitis [19, 20] , as was the case in this patient.
Timely recognition of post donation symptoms and notification to blood banks is important to limit transmission of infectious agents by transfusion [9] . However, post donation report of donor infection is a procedure which is not clearly defined by blood banks, and as a consequence its communication to the donor at time of donation is often neglected. In this case, and although the blood donor had not been adequately instructed, he voluntarily returned to the blood bank with jaundice. If he had not returned to the blood bank, this lookback investigation would not have been initiated, and a case of HAV transmission by transfusion would have gone unnoticed.
Antibody screening tests for HAV is not recommended for serological screening of blood donors in any country, including Brazil [21, 22] . In contrast, after a series of reports definitely proving the transmission of HAV by solvent-detergent-treated factor VIII, the plasma industry now tests all source plasma by HAV NAT [23, 24] . However, due to the sporadic nature of the HAV acute infection among blood donors and the lack of HAV chronic carriers the current recommendation for not screening blood donors for HAV seems adequate. In USA, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends vaccination of all chronic liver disease patients against HAV [25] . Specific groups of immunocompromised patients, especially those going for bone marrow or solid organ transplantation, may benefit from a HAV vaccination program as well. These are also patients that may need continuous blood transfusion support. The R2 case, therefore, underpins the importance of HAV vaccination in immunocompromised as well as chronically infected HCV and HBV patients.
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